BioMarin PharmaceuticalsBMRN
Recorded

BioMarin Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 4 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Thank you for joining us, and welcome to the BioMarin third quarter 2026 conference call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the call over to BioMarin's Head of Investor Relations, Traci McCarty.

Traci McCartyHead of Investor Relations

Please go ahead. Thank you, operator.

Traci McCartyHead of Investor Relations

To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market, and developments by competitors, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K, and 8-K reports. In addition, we will use non-GAAP financial measures as defined in Regulation G during the call today.

Traci McCartyHead of Investor Relations

These non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with U.S. GAAP, and you can find the related reconciliations to U.S. GAAP in the earnings release and earnings presentation, both of which are available in the investor relations section of our website. Please note that our commentary on today's call will focus on non-GAAP financial measures unless otherwise indicated. Beginning on slide 3 and introducing BioMarin's management team joining today's call, Alexander Hardy, Chief Executive Officer, Cristin Hubbard, Chief Commercial Officer, Greg Friberg, Chief R&D Officer, and Brian Mueller, Chief Financial Officer. I will now turn the call over to Alexander to provide our quarterly highlights.

Alexander HardyCEO

Alexander? Thank you, Traci, and thank you all for joining us today.

Alexander HardyCEO

Starting on slide 5, strong demand across our diversified portfolio of innovative therapies drove 32% year-over-year growth in the third quarter, surpassing $1 billion in quarterly revenues for the first time in our history. Also, last week, we announced the addition of a new investigational Fabry asset to our clinical portfolio, recently renamed BMN 450, the fourth new asset added to our pipeline in 2026. This highlights the focused and deliberate expansion of BioMarin's clinical-stage pipeline. BMN 450 has the potential to become the first subcutaneous enzyme therapy to treat people with Fabry, and I will provide more detail in a moment. Moving to our third quarter results, the metabolic conditions business delivered revenue growth of 44% compared to the third quarter of last year, driven by strong contributions from both GALAFOLD and POMBILITI + OPFOLDA.

Alexander HardyCEO

Together, they totaled more than $200 million in combined revenues in the quarter, while at the same time, the pace of the Amicus cost synergies realization exceeded our expectations. We are energized by the addition of our Amicus colleagues, and we are working together to expand the reach of both GALAFOLD and POMBILITI + OPFOLDA, bringing these therapies to more patients around the world. I am also pleased with the continued global expansion of VOXZOGO, as the number of children treated increased by 17% worldwide. Building on this momentum, we are pleased to share that May 30, 2027, is the PDUFA date for VOXZOGO for the treatment of hypochondroplasia, the first targeted therapy to potentially be approved for the indication, and a potential seventh first-in-disease medicine for BioMarin.

Alexander HardyCEO

The team is well prepared for strong launches in hypochondroplasia in the U.S. and Europe, and we anticipate both regions will benefit from our global leadership in skeletal conditions. Before I turn the call over to Cristin, I want to say a few words about the work we are doing to expand our pipeline, including the most recent addition to our clinical portfolio. BMN 450 is a phase I/II compound that builds on our GALAFOLD experience and has the potential to expand the therapeutic reach to those with Fabry whose variants are not amenable to GALAFOLD. BMN 450 is a strategically compelling addition to our metabolic conditions BU, addressing treatment burden, a priority unmet need, with a differentiated, long-acting subcutaneous profile. It also reflects our growing commitment to the Fabry community, building on the Amicus acquisition, as well as the expertise and relationships established with GALAFOLD.

Alexander HardyCEO

In summary, we delivered strong financial results in the third quarter and made meaningful progress across every part of our business. In a moment, Brian will speak to some expected order timing dynamics and geopolitical headwinds that we are observing, resulting in today's updated guidance. In 2026, we have delivered on the strategic expansion of our innovative pipeline, including the addition of BMN 450, BMN 440 for hypophosphatasia, BMN 430 for ReNU syndrome, and BMN 820 for FSGS. Our business development execution, having delivered five deals in two years, demonstrates our capabilities across the value chain as a rare disease leader operating at scale. Our commercial portfolio is now more diversified and more resilient following the successful acquisition of Amicus, as well as our pipeline with the more recently acquired earlier-stage assets.

Alexander HardyCEO

We look ahead with enthusiasm for what is to come as we advance the next wave of therapies from our clinical-stage pipeline and to reporting on a number of key updates in 2027. Combined with the strength of our more diversified commercial portfolio, we are confident in our ability to create lasting value for patients and all of our stakeholders, and we look forward to updating you on our progress. I will now turn the call over to Cristin for more detail on our commercial performance.

Cristin HubbardChief Commercial Officer

Cristin? Thank you, Alexander. The third quarter again showed the strength and growing diversity of our portfolio.

Cristin HubbardChief Commercial Officer

Our team stayed focused on expanding diagnosis, increasing access, and helping more patients start and stay on therapy. Now turning to slide 7. We have begun to implement the initiatives that we outlined last quarter for GALAFOLD and POMBILITI + OPFOLDA. For GALAFOLD, those levers are expanding diagnosis and treatment and deepening market penetration globally. For POMBILITI + OPFOLDA, they are increased patient switching and global market expansion, complemented by improvements in diagnosis and treatment. New geographies take time, so this quarter we focused on the fastest levers: finding and treating more patients in existing markets. We are pleased with the progress we've made in a short amount of time. Both medicines delivered strong revenue in the quarter.

Cristin HubbardChief Commercial Officer

GALAFOLD was $152 million, 10% higher than the $138 million Amicus reported for the third quarter of 2025. POMBILITI + OPFOLDA revenue was $49 million, 58% higher than the $31 million Amicus reported for the same period last year. The number of patients treated with GALAFOLD increased by approximately 13% year-over-year, with growth across both established and newer markets. For example, in the quarter, one international market increased patients on therapy by 20% year-over-year, reflecting the ongoing success of family testing initiatives, bolstered by expanding newborn screening programs. The number of patients on POMBILITI + OPFOLDA increased by approximately 69% year-over-year. Switching continues to be supported by its differentiated clinical profile as we help physicians better identify disease progression on prior therapies.

Cristin HubbardChief Commercial Officer

The expanding body of clinical and real-world evidence reinforces that profile, including the five-year PROPEL extension data presented at the World Muscle Society Congress in October, which Greg will speak to in a moment. We are also seeing an increasing penetration in Europe, where POMBILITI + OPFOLDA is now the market share leader in terms of patients on therapy in four markets. This leadership reflects the growing confidence in the profile of POMBILITI + OPFOLDA. In the third quarter, we also began supporting patients in certain European markets who were affected by recent supply constraints for other Pompe therapies. We have released additional supply so that patients who need it can get treatment without interruption. As a result, patients who switched to POMBILITI + OPFOLDA during the quarter due to supply constraints represented a meaningful share of new patient starts in these markets.

Cristin HubbardChief Commercial Officer

We would expect to see some additional patients in the fourth quarter due to supply constraints for the other Pompe therapies, with the revenue benefits from this dynamic building in 2027 and beyond. Now, we can't predict how long the constraints for other Pompe therapies will last or if it will result in material revenue increases from POMBILITI + OPFOLDA, but reliable supply from BioMarin could become a factor in treatment choice. Now turning to slide 8. Total metabolic conditions revenue was $744 million and grew 44% year-over-year, driven largely by the first full quarter of GALAFOLD and POMBILITI + OPFOLDA. The number of patients on therapy grew across every one of our marketed metabolic conditions brands. Moving to the other products in metabolic conditions, the quarter reflected continued patient demand along with the order timing patterns we have consistently described.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day